SUBSCRIBE: Print / eNewsletter
A recent study found that a group of patients with metastatic castration-resistant prostate cancer responded positively to treatment with ipilimumab, prolonging survival after treatment in the “favorable” cohort.
An international team of researchers created a framework of recommendations to help patients and healthcare professionals make decisions regarding radiation treatment for patients with prostate cancer during the COVID-19 pandemic.
A study found that, utilizing cell-free DNA sequencing leveraging methylation patterns, a new blood test could detect more than 50 cancer types and the location of these cancer types in the body.
Plastic surgeon and breast specialist Dr. Constance Chen discussed the potential complications of implant-based breast reconstruction, and how it compares to natural tissue reconstruction.
Researchers determined that artificial intelligence could help predict responses to systemic therapies for patients with non-small cell lung cancer by utilizing CT scans.
A recent study analyzed response to treatment of oligometastatic prostate cancer with stereotactic ablative radiotherapy and found improved oncologic outcomes among men.
A study with a small sample size revealed that trastuzumab deruxtecan showed promising activity in multiple HER2-expressing or HER2-mutant solid tumors.
This study examined the acquired resistance found from treatment with third-generation EGFR TKIs to see if it was associated with diverse pathways, with an eye for the EGFR T790M mutation.
A study analyzed a test for specific gene patterns that could indicate that a patient will not respond to standard treatment for newly diagnosed multiple myeloma.
Genentech recently announced their phase III study resulted in improved overall survival and composite complete remission rates for patients with previously untreated acute myeloid leukemia.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
